Accelerate New York Seed Fund

Cress Health is a company focused on improving mental wellness for individuals and organizations through innovative technology. It has developed a digital healthcare platform that allows users to track their daily emotions, connect with peers, and share experiences. This platform provides personalized reports that help users gain insights into their mental health, fostering self-understanding and community support. By leveraging these tools, Cress Health aims to enhance overall mental wellness and create a supportive environment for users seeking to improve their mental health.

Fuell is a manufacturer of premium electric mobility solutions aimed at providing alternatives to traditional car transportation in urban environments. The company focuses on developing e-vehicles that prioritize safety and advanced technology, tailored specifically to meet the needs of urban riders. By combining the expertise of its founders, Fuell creates an innovative riding experience that enhances urban mobility. In addition to its electric vehicles, Fuell offers digital services designed to enrich the overall experience of navigating cities, positioning itself as a leader in the evolution of urban transportation.

Qunnect, LLC is a technology company based in Stony Brook, New York, specializing in the development of light-based modular devices for ultra-secure information networks. Founded in 2017 as a spin-off from the Quantum Information Technology group at Stony Brook University, Qunnect designs quantum hardware that facilitates the transmission, storage, and receipt of encrypted information using principles of quantum physics. The company's innovations include quantum memories and sources that enhance communication networks and quantum computing capabilities. Additionally, Qunnect's field-deployable systems support long-distance, quantum-secured communication, complemented by an AI-enabled software suite that monitors network components in real-time. This technology aims to address the evolving needs of cybersecurity by enabling real-time threat detection and fostering the development of scalable quantum-secure networks.

Goldilocks Therapeutics is a biotechnology company founded in 2018 and based in Bedford, New York. The company focuses on developing preventative treatments for acute kidney injury, polycystic kidney disease, and other renal conditions. Goldilocks Therapeutics utilizes proprietary mesoscale nanoparticles to specifically target therapeutic payloads to the renal tubule epithelium, allowing for sustained-release delivery of medications. This innovative approach aims to enhance treatment efficacy and improve the lives of patients suffering from kidney-related ailments.

CalmiGo is a company that develops a portable, drug-free medical device aimed at providing immediate relief from emotional and mental distress. The device utilizes advanced technology to help users manage moments of anxiety, stress, and distress by regulating their breathing patterns and stimulating their senses. This innovative solution is designed to be accessible to individuals of all ages and varying technical abilities, allowing them to address anxiety-related issues effectively, regardless of their location. By focusing on a natural approach, CalmiGo offers a convenient and immediate alternative for those seeking relief without the use of medication.

HashLynx Inc. is a Middletown, New York-based company founded in 2018 that specializes in designing and developing a platform for trade matching and settlement in the capital markets. The company leverages smart contract technology to enhance the efficiency and transparency of trading and settlement processes. By offering a seamless, open-architecture platform, HashLynx facilitates easy integration with existing front- and back-end legacy loan systems, allowing clients to significantly reduce the time and costs associated with syndicated lending transactions. Through its innovative blockchain solutions and financial expertise, HashLynx aims to transform the landscape of capital markets.

Aspisafe Solutions is a medical device company specializing in the development of innovative feeding medical devices, including catheters, feeding tubes, nasogastric tubes, and nasogastric tube holders. The company's flagship product is a nasogastric tube that employs proprietary balloon pressure technology to effectively prevent stomach reflux and aspiration in intubated patients. This technology enhances patient comfort and safety by securely maintaining the intubation catheter in place while reducing the risk of aspiration-related complications, such as pneumonia. Aspisafe Solutions is dedicated to addressing critical healthcare challenges associated with feeding and aspiration in vulnerable patient populations.

Toggle is a United States-based company that specializes in robotics as a service (RaaS) for the construction industry. It focuses on automating the assembly of rebar cages for reinforced concrete applications, enhancing efficiency and precision in construction processes. Toggle's offerings include two-arm robotic platforms and proprietary jig designs capable of constructing various shapes directly from computer blueprints. In addition to its core services, the company also provides pre-assembly solutions, contributing to the advancement of robotics and automation in the construction sector.

TargaGenix, Inc., established in 2013 and headquartered in Stony Brook, New York, specializes in developing innovative compounds targeting drug-resistant tumors and cancer stem cells. Its flagship product, SBT-1214, has demonstrated promising results in preclinical models of colon, pancreatic, prostate, breast, and lung cancers, showing the ability to eliminate tumors entirely. Furthermore, SBT-1214 effectively downregulates "stemness" gene expression and kills cancer stem cells. Through chemical modifications and a novel fatty-acid based nanoemulsion formulation, the drug's pharmacokinetics, pharmacodynamics, and toxicity profile have been enhanced.

EpiVax Oncology is a biotechnology company focused on developing personalized immunotherapies for cancer treatment. Based in New York, the company specializes in precision cancer mutanome-directed and neo-epitope therapies, utilizing advanced immuno-oncology and neoantigen discovery solutions. EpiVax Oncology's platform relies on optimal neo-epitopes selected through proprietary, validated predictive algorithms to address unmet medical needs that current cancer therapeutic approaches do not adequately cover. The company was established in 2017 with the goal of providing innovative clinical research and development platforms for various types of precision cancer immunotherapies.

Concarlo Therapeutics is a preclinical-stage oncology company focused on developing innovative therapies to combat drug-resistant cancers. The firm aims to transform cancer treatment by targeting the p27 protein, a natural inhibitor of CDK4/CDK6 and CDK2, to effectively kill tumor cells rather than merely halting their growth. Concarlo utilizes patented technologies to enhance drug efficacy and broaden its addressable market, particularly in advanced tumor types such as metastatic breast cancer and various orphan cancers, including ovarian and pancreatic cancers. By addressing critical issues of drug resistance with specificity and low toxicity, Concarlo's approach seeks to improve patient outcomes and make cancer a more manageable and survivable condition.

Frenzy Labs, Inc. is a technology company that specializes in developing a visual search application platform to enhance image monetization for websites. Founded in 2017 and based in Marina Del Rey, California, Frenzy utilizes deep learning algorithms and computer vision to analyze website images, accurately identifying brands and products even in complex visual scenes without logos. The company offers various solutions, including self-labeling image technology that significantly reduces the need for manual labeling, thereby improving efficiency in managing image datasets. Frenzy's products include Fetch, a content monetization plugin tailored for fashion bloggers, and Frenzy Enterprise Solutions, which provides automated catalog management and precise image search capabilities for e-commerce platforms. By enabling users to seamlessly monetize their site images, Frenzy helps streamline the online shopping experience while minimizing the time and effort required to identify products.

Mirow LLC is a New York-based company founded in 2016 that specializes in manufacturing smart mirrors for fitting rooms, designed to enhance the retail experience. These interactive mirrors utilize touch technology and sensors to identify customer preferences, offering personalized recommendations, information on discounts, and automated assistance. Customers can easily call for sales support or request items in different sizes or colors directly from the fitting room. Mirow's innovative approach not only improves the quality of service but also provides retailers with valuable insights into customer behavior and preferences. The company has gained recognition in the retail and hospitality sectors and is expanding its presence in both the US and EU markets, serving a range of top-tier brands.

Digitouch Health is a medical device company based in Valhalla, New York, specializing in the development of a smartphone device that enables users to measure and track their blood pressure. The device utilizes advanced algorithm-enabled technology and oscillometry to provide accurate blood pressure readings without the need for calibration. It facilitates the monitoring of hypertension and allows for the seamless transmission of data to electronic health records, thereby enhancing patient convenience and ensuring clinical accuracy. By collaborating with healthcare practitioners, Digitouch Health aims to support individuals in managing their cardiovascular health, ultimately contributing to longer and healthier lives.

Bioharmony Therapeutics, Inc. is a biotechnology company focused on developing lysin-based antimicrobial therapeutics specifically designed to combat multi-drug resistant Gram-negative bacterial infections. Incorporated in 2016 and headquartered in New York, Bioharmony Therapeutics specializes in creating innovative treatments that target skin infections caused by pathogens such as Acinetobacter baumannii. Their therapeutics work by disrupting the bacterial cell wall, offering potential solutions for serious conditions like hospital-acquired pneumonia and critical blood or wound infections. Through its advancements in bacteriophage technology, the company aims to provide effective treatments for patients facing the challenges of antibiotic resistance.

DepYmed is a pharmaceutical company based in Cold Spring Harbor, New York, focused on developing therapeutics for breast cancer and rare diseases. The company specializes in creating potent inhibitors of the enzyme PTP1B (protein tyrosine phosphatase 1B) for HER2-positive breast cancer and Rett Syndrome. Additionally, DepYmed has developed a portfolio of novel small molecules with copper-chelating properties, which have potential applications in treating Wilson Disease and various cancers. The company collaborates with Cold Spring Harbor Laboratory to advance these therapeutic agents through preclinical development.

PainQx, Inc. is a healthcare software company founded in 2015 and based in New York, New York. The company specializes in developing innovative solutions for objectively measuring pain in both humans and veterinary applications. Its flagship offering, the PainQx System, utilizes advanced algorithms to analyze neural activity from a patient's brain, producing a scalable biomarker that correlates with the patient's pain state and neurological side effects. This diagnostic tool serves as a clinical assessment method for various organizations, particularly in evaluating the efficacy of drugs and devices where pain is a critical endpoint. PainQx operates on a pay-per-use or subscription model, catering to the needs of medical professionals and researchers aiming for accurate pain assessment, especially in populations that struggle to communicate their pain effectively.

Paladin is a legal technology company founded in 2015 and based in New York, USA. The firm has developed a platform that connects attorneys with vetted pro bono opportunities, allowing legal professionals to engage in cases that align with their passions. By streamlining the process of creating, distributing, and managing pro bono matters, Paladin enables law firms, bar associations, and corporations to enhance their service delivery to low-income individuals. Additionally, the platform facilitates the tracking of lawyers' contributions and captures impact data, highlighting the positive effects of their efforts. Through its services, Paladin aims to enhance pro bono participation and support the legal community in addressing access to justice.

ENB Therapeutics, Inc. is a biopharmaceutical company based in New York, New York, that specializes in developing small molecule inhibitors aimed at treating melanoma and other cancers. Founded in 2015, the company focuses on overcoming drug resistance, a significant issue affecting over 50% of cancer patients. Its lead product, ENB-001, is a first-in-class selective endothelin B receptor (ETBR) inhibitor that has demonstrated the ability to significantly reduce tumor growth and enhance survival in preclinical studies. ENB-001 works by restoring T-cell infiltration into tumors, inhibiting metastasis, and improving the efficacy of immunotherapy. The product has received Orphan Drug Designation from the FDA, granting it market exclusivity and a robust intellectual property position. ENB Therapeutics is also developing a companion diagnostic to identify patients who could benefit from ENB-001, thus broadening its potential applications within the multi-billion-dollar immunotherapy market. The company's innovative approach aims to set a new standard of care by combining its therapies with existing immuno-oncology treatments to combat drug resistance and stimulate immune responses against cancer.

Mymee, Inc. is a New York-based company that specializes in remote care and support services for individuals with chronic rheumatic and neurological autoimmune diseases. Founded in 2011, Mymee has developed a software-as-a-service health coaching platform that identifies non-obvious triggers for symptoms through personalized analysis of users' daily lives. The platform focuses on dietary and environmental factors that may contribute to disease flares and creates tailored care plans to address these triggers. By combining expert health coaching with behavioral change strategies, Mymee aims to enhance the quality of life for its users. Clinical trials have shown that participants experience significant improvements in various health-related quality of life domains, including fatigue and pain. Through the support of certified health coaches, Mymee empowers individuals to take control of their health and adopt habits that may help reverse their symptoms.

Marvel Genomics is a biotechnology company focused on developing genetic tests to identify young children at risk for autism. By utilizing advanced genomic diagnostics, the company aims to create precise genetic tests, including a proprietary device for detecting Copy Number Variation. This innovative approach enables early identification of children at risk for autism and other genetic-based diseases, facilitating timely clinical intervention and therapy. Marvel Genomics is dedicated to improving outcomes through early diagnosis, allowing patients and their families to access appropriate treatments and support services effectively.